Comparison between different therapeutic sequences in patients affected by metastatic pancreatic ductal adenocarcinoma.
Clinical endpoint
Therapeutic effect
DOI:
10.1200/jco.2024.42.3_suppl.674
Publication Date:
2024-01-22T21:12:58Z
AUTHORS (20)
ABSTRACT
674 Background: The first-line treatment of metastatic pancreatic cancer involves different therapeutic regimens, among them, mFOLFIRINOX and gemcitabine-nabpaclitaxel. However, it remains to be clarified which sequence might correlate with better outcomes. aim our work was evaluate leads overall survival in this setting. Methods: We retrospectively collected data from 358 patients affected by stage IV ductal adenocarcinoma 3 Italian Institutions. Patients received or gemcitabine plus nabpaclitaxel as chemotherapy, followed a second-line non-cross-resistant chemotherapy (gemcitabine fluoropyrimidine-based combinations). Survival distribution assessed Kaplan-Meier curves. primary endpoint median survival. Statistical analysis performed MedCalc package. Results: age 66 (± 9), 195 (54,4%) were male 163 (45,6%) female. 292 (81,5%) start first line treatment, while (18,5%) therapy. No statistically significant differences terms mOS observed between the two gemcitabine-nabpaclitaxel groups: 16 versus 15 months, respectively, p = 0,2). found mPFS either: 7 8 0,3). Conclusions: results retrospective study showed no advantage sequences starting Further studies will necessary establish effectiveness new schemes introduced into clinical practice order define algorithm.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (0)
CITATIONS (0)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....